SCHEMBL2322162

SCHEMBL2322162

CCOP(=O)(O)CC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
TDP1 Q9NUW8 4/20 0.53
MEN1 O00255 3/20 0.53
NR1I2 O75469 1/20 0.53
ALDH1A1 P00352 3/20 0.51
MAPK1 P28482 1/20 0.51
HIF1A Q16665 1/20 0.51
POLB P06746 2/20 0.48
THRB P10828 1/20 0.48
RECQL P46063 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324765 0.89 TAS1R3 (0.47) KMT2ATDP1MEN1NR1I2ALDH1A1
SCHEMBL2329637 0.87 TDP1 (0.43) KMT2ATDP1MEN1NR1I2ALDH1A1
SCHEMBL1549681 0.86 KMT2A (0.42) KMT2ATDP1MEN1NR1I2MAPK1
SCHEMBL2322233 0.82 ERCC5 (0.44) KMT2AMEN1ALDH1A1POLBTHRB
SCHEMBL1549852 0.80 HTT (0.41) KMT2ATDP1MEN1NR1I2KDM4E
SCHEMBL2322050 0.80 POLB (0.43) KMT2ATDP1MEN1NR1I2ALDH1A1
SCHEMBL2322156 0.78 ALDH1A1 (0.56) KMT2ATDP1MEN1NR1I2ALDH1A1
SCHEMBL2324686 0.77 TAS1R3 (0.47) KMT2AMEN1ERCC5FEN1MAPT
SCHEMBL2322311 0.75 SMN1; SMN2 (0.44) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2328992 0.75 NPC1 (0.40) KMT2ATDP1MEN1NR1I2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 KMT2A 2891/4885TDP1 913/4885MEN1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.